Extracellular Cyclophilin A Augments Platelet-Dependent Thrombosis and Thromboinflammation

Abstract

Cyclophilin A (CyPA) is involved in the pathophysiology of several inflammatory and cardiovascular diseases. To our knowledge, there is no specific inhibitor targeting extracellular CyPA without affecting other extracellular cyclophilins or intracellular CyPA functions. In this study, we developed an antibody-based inhibitor of extracellular CyPA and analysed its effects in vitro and in vivo. To generate a specific antibody, mice and rats were immunized with a peptide containing the extracellular matrix metalloproteinase inducer binding site and various antibody clones were selected and purified. At first, antibodies were tested for their binding capacity to recombinant CyPA and their functional activity. The clone 8H7-mAb was chosen for further experiments. 8H7-mAb reduced the CyPA-induced migration of inflammatory cells in vitro and in vivo. Furthermore, 8H7-mAb revealed strong antithrombotic effects by inhibiting CyPA-dependent activation of platelets and thrombus formation in vitro and in vivo. Surprisingly, 8H7-mAb did not influence in vivo tail bleeding time or in vitro whole blood coagulation parameters. Our study provides first evidence that antibody-based inhibition of extracellular CyPA inhibits thrombosis and thromboinflammation without affecting blood homeostasis. Thus, 8H7-mAb may be a promising compound for thrombi modulation in inflammatory diseases to prevent organ dysfunction.

Keywords

cyclophilin A - thrombosis - inflammation - platelets

Sources of Funding

This work has been supported, in part, by grants from the Deutsche Forschungsgemeinschaft (Transregio SFB19 and the Klinische Forschergruppe KFO274), the Tuebingen Platelet Investigative Consortium (TuePIC) and the NIH (1S10OD019973–01 and 1R35GM119526–01).

• References

• 1 Fischer G, Wittmann-Liebold B, Lang K, Kiefhaber T, Schmid FX. Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature 1989; 337 (6206): 476-478
• 2 Galigniana MD, Morishima Y, Gallay PA, Pratt WB. Cyclophilin-A is bound through its peptidylprolyl isomerase domain to the cytoplasmic dynein motor protein complex. J Biol Chem 2004; 279 (53) 55754-55759
• 3 Rosado JA, Pariente JA, Salido GM, Redondo PC. SERCA2b activity is regulated by cyclophilins in human platelets. Arterioscler Thromb Vasc Biol 2010; 30 (03) 419-425
• 4 Kern G, Kern D, Schmid FX, Fischer G. Reassessment of the putative chaperone function of prolyl-cis/trans-isomerases. FEBS Lett 1994; 348 (02) 145-148
• 5 Baker EK, Colley NJ, Zuker CS. The cyclophilin homolog NinaA functions as a chaperone, forming a stable complex in vivo with its protein target rhodopsin. EMBO J 1994; 13 (20) 4886-4895
• 6 Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 1984; 226 (4674): 544-547
• 7 Colgan J, Asmal M, Neagu M. , et al. Cyclophilin A regulates TCR signal strength in CD4+ T cells via a proline-directed conformational switch in Itk. Immunity 2004; 21 (02) 189-201
• 8 Colgan J, Asmal M, Yu B, Luban J. Cyclophilin A-deficient mice are resistant to immunosuppression by cyclosporine. J Immunol 2005; 174 (10) 6030-6038
• 9 Coppinger JA, Cagney G, Toomey S. , et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004; 103 (06) 2096-2104
• 10 Sherry B, Yarlett N, Strupp A, Cerami A. Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages. Proc Natl Acad Sci U S A 1992; 89 (08) 3511-3515
• 11 Kim SH, Lessner SM, Sakurai Y, Galis ZS. Cyclophilin A as a novel biphasic mediator of endothelial activation and dysfunction. Am J Pathol 2004; 164 (05) 1567-1574
• 12 Seizer P, Ungern-Sternberg SN, Schönberger T. , et al. Extracellular cyclophilin A activates platelets via EMMPRIN (CD147) and PI3K/Akt signaling, which promotes platelet adhesion and thrombus formation in vitro and in vivo. Arterioscler Thromb Vasc Biol 2015; 35 (03) 655-663
• 13 Yuan W, Ge H, He B. Pro-inflammatory activities induced by CyPA-EMMPRIN interaction in monocytes. Atherosclerosis 2010; 213 (02) 415-421
• 14 Kasinrerk W, Fiebiger E, Stefanová I, Baumruker T, Knapp W, Stockinger H. Human leukocyte activation antigen M6, a member of the Ig superfamily, is the species homologue of rat OX-47, mouse basigin, and chicken HT7 molecule. J Immunol 1992; 149 (03) 847-854
• 15 Chen X, Kanekura T, Kanzaki T. Expression of Basigin in human fetal, infantile and adult skin and in basal cell carcinoma. J Cutan Pathol 2001; 28 (04) 184-190
• 16 Schmidt R, Bültmann A, Fischel S. , et al. Extracellular matrix metalloproteinase inducer (CD147) is a novel receptor on platelets, activates platelets, and augments nuclear factor kappaB-dependent inflammation in monocytes. Circ Res 2008; 102 (03) 302-309
• 17 Yang Y, Lu N, Zhou J, Chen ZN, Zhu P. Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes/macrophages via CD147 signalling pathway in rheumatoid arthritis. Rheumatology (Oxford) 2008; 47 (09) 1299-1310
• 18 Heinzmann D, Bangert A, Müller AM. , et al. The novel extracellular cyclophilin A (CyPA)-inhibitor MM284 reduces myocardial inflammation and remodeling in a mouse model of troponin I-induced myocarditis. PLoS One 2015; 10 (04) e0124606
• 19 Seizer P, Klingel K, Sauter M. , et al. Cyclophilin A affects inflammation, virus elimination and myocardial fibrosis in coxsackievirus B3-induced myocarditis. J Mol Cell Cardiol 2012; 53 (01) 6-14
• 20 Seizer P, Ochmann C, Schönberger T. , et al. Disrupting the EMMPRIN (CD147)-cyclophilin A interaction reduces infarct size and preserves systolic function after myocardial ischemia and reperfusion. Arterioscler Thromb Vasc Biol 2011; 31 (06) 1377-1386
• 21 Billich A, Hammerschmid F, Peichl P. , et al. Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions. J Virol 1995; 69 (04) 2451-2461
• 22 Malesević M, Kühling J, Erdmann F. , et al. A cyclosporin derivative discriminates between extracellular and intracellular cyclophilins. Angew Chem Int Ed Engl 2010; 49 (01) 213-215
• 23 Kallen J, Spitzfaden C, Zurini MG. , et al. Structure of human cyclophilin and its binding site for cyclosporin A determined by X-ray crystallography and NMR spectroscopy. Nature 1991; 353 (6341): 276-279
• 24 Ke HM, Zydowsky LD, Liu J, Walsh CT. Crystal structure of recombinant human T-cell cyclophilin A at 2.5 A resolution. Proc Natl Acad Sci U S A 1991; 88 (21) 9483-9487
• 25 Harding MW, Handschumacher RE, Speicher DW. Isolation and amino acid sequence of cyclophilin. J Biol Chem 1986; 261 (18) 8547-8555
• 26 Schmidt R, Bültmann A, Ungerer M. , et al. Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: implications in acute myocardial infarction. Circulation 2006; 113 (06) 834-841
• 27 Ziegler M, Elvers M, Baumer Y. , et al. The bispecific SDF1-GPVI fusion protein preserves myocardial function after transient ischemia in mice. Circulation 2012; 125 (05) 685-696
• 28 May AE, Schmidt R, Bülbül BO. , et al. Plasminogen and matrix metalloproteinase activation by enzymatically modified low density lipoproteins in monocytes and smooth muscle cells. Thromb Haemost 2005; 93 (04) 710-715
• 29 Elvers M, Herrmann A, Seizer P. , et al. Intracellular cyclophilin A is an important Ca(2+) regulator in platelets and critically involved in arterial thrombus formation. Blood 2012; 120 (06) 1317-1326
• 30 Seizer P, Borst O, Langer HF. , et al. EMMPRIN (CD147) is a novel receptor for platelet GPVI and mediates platelet rolling via GPVI-EMMPRIN interaction. Thromb Haemost 2009; 101 (04) 682-686
• 31 Borst O, Schaub M, Walker B. , et al. Pivotal role of serum- and glucocorticoid-inducible kinase 1 in vascular inflammation and atherogenesis. Arterioscler Thromb Vasc Biol 2015; 35 (03) 547-557
• 32 Rolle AM, Hasenberg M, Thornton CR. , et al. ImmunoPET/MR imaging allows specific detection of Aspergillus fumigatus lung infection in vivo. Proc Natl Acad Sci U S A 2016; 113 (08) E1026-E1033
• 33 Disselhorst JA, Bezrukov I, Kolb A, Parl C, Pichler BJ. Principles of PET/MR Imaging. J Nucl Med 2014; 55 (Suppl. 02) 2S-10S
• 34 Borst O, Münzer P, Gatidis S. , et al. The inflammatory chemokine CXC motif ligand 16 triggers platelet activation and adhesion via CXC motif receptor 6-dependent phosphatidylinositide 3-kinase/Akt signaling. Circ Res 2012; 111 (10) 1297-1307
• 35 Borst O, Schmidt EM, Münzer P. , et al. The serum- and glucocorticoid-inducible kinase 1 (SGK1) influences platelet calcium signaling and function by regulation of Orai1 expression in megakaryocytes. Blood 2012; 119 (01) 251-261
• 36 Darwiche SS, Kobbe P, Pfeifer R, Kohut L, Pape HC, Billiar T. Pseudofracture: an acute peripheral tissue trauma model. J Vis Exp 2011; 50 (50) 2074
• 37 Vogel S, Bodenstein R, Chen Q. , et al. Platelet-derived HMGB1 is a critical mediator of thrombosis. J Clin Invest 2015; 125 (12) 4638-4654
• 38 Bass LA, Wang M, Welch MJ, Anderson CJ. In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjug Chem 2000; 11 (04) 527-532
• 39 Vogel S, Chatterjee M, Metzger K. , et al. Activated platelets interfere with recruitment of mesenchymal stem cells to apoptotic cardiac cells via high mobility group box 1/Toll-like receptor 4-mediated down-regulation of hepatocyte growth factor receptor MET. J Biol Chem 2014; 289 (16) 11068-11082
• 40 Ma S, Boerner JE, TiongYip C. , et al. NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon. Antimicrob Agents Chemother 2006; 50 (09) 2976-2982
• 41 Wang L, Soe NN, Sowden M. , et al. Cyclophilin A is an important mediator of platelet function by regulating integrin αIIbβ3 bidirectional signalling. Thromb Haemost 2014; 111 (05) 873-882
• 42 Yurchenko V, Zybarth G, O'Connor M. , et al. Active site residues of cyclophilin A are crucial for its signaling activity via CD147. J Biol Chem 2002; 277 (25) 22959-22965
• 43 Arora K, Gwinn WM, Bower MA. , et al. Extracellular cyclophilins contribute to the regulation of inflammatory responses. J Immunol 2005; 175 (01) 517-522
• 44 Damsker JM, Bukrinsky MI, Constant SL. Preferential chemotaxis of activated human CD4 + T cells by extracellular cyclophilin A. J Leukoc Biol 2007; 82 (03) 613-618
• 45 Seizer P, Schönberger T, Schött M. , et al. EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation. Atherosclerosis 2010; 209 (01) 51-57
• 46 Braaten D, Ansari H, Luban J. The hydrophobic pocket of cyclophilin is the binding site for the human immunodeficiency virus type 1 Gag polyprotein. J Virol 1997; 71 (03) 2107-2113
• 47 Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998; 94 (05) 657-666
• 48 Savage B, Saldívar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996; 84 (02) 289-297
• 49 Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8 (11) 1227-1234
• 50 Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115 (12) 3378-3384
• 51 Tegeder I, Schumacher A, John S. , et al. Elevated serum cyclophilin levels in patients with severe sepsis. J Clin Immunol 1997; 17 (05) 380-386
• 52 Billich A, Winkler G, Aschauer H, Rot A, Peichl P. Presence of cyclophilin A in synovial fluids of patients with rheumatoid arthritis. J Exp Med 1997; 185 (05) 975-980
• 53 Investigators E. ; EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330 (14) 956-961
• 54 Koren MJ, Lundqvist P, Bolognese M. , et al; MENDEL-2 Investigators. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol 2014; 63 (23) 2531-2540